Insys Therapeutics, Inc. (INSY) Will SYNDROS Potential Replace SUBSYS Challenges

Insys Therapeutics, Inc. (INSY) Will SYNDROS Potential Replace SUBSYS Challenges

0 586

Will SYNDROS Potential Replace SUBSYS Challenges

Insys has been the subject of negative publicity as state and federal investigations continue against six ex-employees regarding the sales and billing practices of the company in the past. The investigations surround the company’s drug, Subsys, a fentanyl-based sublingual spray used for the treatment of cancer patients.

Insys issued a response to recent media reports by reiterating its commitment towards the highest ethical standards and compliance with all its activities and business practices and complying with governing laws and regulations and cooperating with relevant governmental authorities in ongoing investigations. Management also highlighted that Insys intends to play a meaningful role in providing solutions to address the opioid epidemic by developing innovative products. These potential product solutions include cannabidiol (a novel, non-opioid) for the treatment of opioid dependence, for the treatment of pain and naloxone nasal spray for the treatment of opioid overdose.

Will INSYS continue with SUBSYS, what the analysts say and Q1 review: READ MORE.

Copy and paste to your browser may be required to view the report -http://tradersnewssource.com/insy/.

On the brighter side, FDA approved the final labeling for Syndros (dronabinol oral solution, a pharmaceutical version of THC), which may classify the drug as a Schedule II controlled substance. Insys expects to launch the product in August 2017. Syndros is indicated for the treatment of anorexia associated with weight loss in patients with AIDS and in the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Syndros will be a direct competitor to Marinol, a product offered by Abbvie in pill form. Since Syndros is a liquid, it should be easier to swallow and can be administered in prescribed dosages. Dronabinol was approved by the FDA decades ago as a treatment option for cancer patients. Today, the potential applications for dronabinol, including sleep apnea and opioid dependency, could catapult this drug to annual sales in the billions.

Details of SYNDROS development and its potential: READ MORE.

Copy and paste to your browser may be required to view the report -http://tradersnewssource.com/insy/.

DISCLOSURE

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, article, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated, directly or indirectly, for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO COMMENTS

Leave a Reply